{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"8.5","value":"2.6"}]}]}],"denomUnitsSelected":"courses","denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"47"}],"units":"courses"}],"description":"For the subset of patients with metastatic disease (high-risk group patients), during consolidation, we will calculate the number and proportion of courses during which subsequent chemotherapy administration was delayed for more than 7 days due to toxicity. Patients were to received 2 courses of consolidation chemotherapy and then maintenance therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG000","title":"High-Risk Group"}],"paramType":"NUMBER","populationDescription":"Eligible high-risk group patients who started therapy were included. Course 2 of consolidation and the 1st course of maintenance were used in this analysis and assessed for delays \\>7 days due to toxicity. Of the 76 high-risk patients that started induction therapy, 50 started consolidation (with 47 courses included in this analysis).","reportingStatus":"POSTED","timeFrame":"At completion of consolidation therapy (up to 6 months after on-study date)","title":"Feasibility and Toxicity of Administering Consolidation Therapy Including Cyclophosphamide and Pharmacokinetically Targeted Topotecan to Patients With Metastatic Disease Based on the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity","type":"SECONDARY","typeUnitsAnalyzed":"courses","unitOfMeasure":"Percentage of courses delayed"}